Cancer immunotherapy market set to grow to nearly $9 billion across major markets in 2022

1 July 2014

The cancer immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8% annual growth) in the USA, France, Germany, Italy, Spain, UK and Japan.

This impressive growth will be driven by the expected market entry of nine novel immunotherapies - including four novel immune checkpoint inhibitors and five novel therapeutic vaccines - in new oncology indications and/or patient populations, according to a new report from Decision Resources Group.

Taken together, Bristol-Myers Squibb’s (NYSE: BMY) anti-CTLA-4 agent Yervoy (ipilimumab) and novel immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway - including Bristol-Myers /Ono Pharmaceutical’s nivolumab, Merck & Co’s (NYSE: MRK) pembrolizumab (MK-3475), Roche (ROG: SIX)/Genentech/Chugai’s MPDL-3280A and AstraZeneca (LSE: AZN)/MedImmune’s MEDI4736 - will dominate the immunotherapy market and capture a staggering 85% market share in 2022.

Other key findings from the Pharmacor Immunotherapies advisory service include:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK